



## EPITHELIOID HEMANGIOENDOTHELIOMA OF CHEST WALL: CASE REPORT

### General Surgery

|                                  |   |
|----------------------------------|---|
| <b>Dr.Karuppiah.K</b>            | Post Graduatte Department of General Surgery, Meenakshi Medical College & Hospital And Research Institute, Kanchipuram, Tamilnadu.                      |
| <b>Dr. Gowtham Pandiaraj. K*</b> | Post Graduatte Department of General Surgery, Meenakshi Medical College & Hospital And Research Institute, Kanchipuram, Tamilnadu.*Corresponding Author |
| <b>Dr.Pawan Kumar Reddy</b>      | Post Graduatte Department of General Surgery, Meenakshi Medical College & Hospital And Research Institute, Kanchipuram, Tamilnadu.                      |
| <b>Dr.Ravi.P</b>                 | Professor Department of General Surgery, Meenakshi Medical College & Hospital And Research Institute, Kanchipuram, Tamilnadu.                           |

### ABSTRACT

Epithelioidhemangioendothelioma (EHE) is a rare vascular tumor, first described by Sharon Weiss and Franz Enzinger in 1982 as an intermediate condition between hemangioma(benign) and angiosarcoma(malignant) both clinically and pathologically[1][3]. However, with the advent of cytogenetics,EHE is now considered as a distinct entity with distinct disease defining genetic alteration. Because of its rarity and varied anatomical locations, EHE has got no standard treatment plan[3]. With the treatment options being surgical resection, chemotherapy, radiotherapy, measures inhibiting angiogenesis, etc. We report a case of chest wall epithelioidhemangioendothelioma, a solitary lesion with easy accessibility for curative resection, making it the best treatment option for the same.

### KEYWORDS

#### INTRODUCTION:

EHE was originally described as vascular tumor arising from endothelial cells most commonly in the small veins of the extremities (upper and lower limbs) and the liver and lungs. It has since been described in organs throughout the body.

#### Other Sites Of Epithelioid Hemangioendothelioma [3].

|                 |                        |
|-----------------|------------------------|
| Head and neck   | Breast                 |
| Lymph nodes     | Mediastinum            |
| Diaphragm       | Brain and meninges     |
| Mastoid         | Infundibulum           |
| Clivus          | Cerebellopontine angle |
| Spine           | Skin                   |
| Peritoneum      | Stomach                |
| Retroperitoneum | Ovary                  |
| Prostate        | Eyelid                 |

We report a case of EHE arising from chest wall, a rare site for a rare tumor and its review of literature.



Fig 1: Pre operative image



Fig 2: X-ray image

#### CASE REPORT:

A82 years old male presented with swelling over right scapular region for 9 years, which was insidious in onset and gradually progressing. But following a trauma to the same, 1 year back it has rapidly increased in size. His past history was unremarkable except for excision of similar swelling at 10 yrs of age over right lumbar region. On examination, he had a single huge non compressible swelling of size 40 \* 30 cm over right scapular region. It was a freely mobile, fluctuant swelling with mixed consistency (predominantly cystic) and presented

with skin excoriations (Fig 1).Clinically, soft tissue sarcoma was suspected and magnetic resonance imaging was done.Fine Needle Aspiration Cytology was done for tissue diagnosis.



Fig 3: MRI image



Fig 4: Post operative specimen.

#### DISCUSSION:

Epithelioidhemangioendothelioma is a rare vascular tumor with an epithelioid and histiocytoid appearance, originating from vascularendothelial or pre-endothelial cells. It represents less than 1% of all vascular tumors and was described for the first time in 1975 by Dailand Liebowas pulmonary EHE (P-EHE).The term "epithelioidhemangioendothelioma"was introduced in 1982by Weiss and Enzinger to describe a vascular tumor of bone and softtissue showing features between hemangioma and angiosarcoma[1].

The recent World Health Organization (WHO 2002) classificationdescribes EHE as lesions that fall into the category of locally aggressivetumors with metastatic potential[6][7].The estimated prevalence of EHE is less than one in 1 million[1].According to (WHO) classificationof Tumors of bone and soft tissues (2002), one half to two thirdsof them originates from a vessel (such as a small vein). Exceptionally,it may originate from a large vein or artery.

**ETIOPATHOGENESIS:** Many things have been speculated as potential causes of EHE, including hormonal effects, oral contraceptive pills, industrial exposures (vinyl chloride) and trauma among others. None of these associations has been confirmed. Fortunately, significant progress has been made very recently. Two separate research groups published findings in late 2011 indicating a specific chromosomal translocation that is virtually diagnostic for EHE. This swapping of genetic material between chromosomes 1 and

3 is seen in almost all EHE tumor cells and can be considered 'disease defining'[2]. This genetic alteration results in the production of a fusion gene and a resulting fusion protein. It has part of a protein that is normally seen only in endothelial cells and another part seen only in brain. This abnormal fusion protein presumably causes the cells to grow without normal regulation.

A new, suggestive hypothesis of the pathogenesis of this disease refers to a causal relationship between chronic Bartonella infection and the development of this rare vascular tumor. The unique Bartonella's capability of invading and inducing long-lasting intraerythrocytic and intraendothelial infections, together with the ability of at least three Bartonella spp. (*B. henselae*, *B. quintana*, *B. bacilliformis*) of inducing vascular endothelial growth factor-mediated vasoproliferation as they upregulate mitogen and proinflammatory genes resulting in cytoskeletal rearrangement and suppression of endothelial cell apoptosis, suggest that these bacterial pathogens might contribute to the development of vascular tumors.[8]

**CLINICAL FEATURES:** The clinical presentation of this rare vascular tumor is as heterogeneous as its clinical localization can be:

| SITE            | CLINICAL FEATURES                                     | TREATMENT                       |
|-----------------|---|---------------------------------|
| FOREHEAD        | Nodular skin lesion, Visual disturbance               | Surgery                         |
| ABDOMINAL WALL  | Swelling  | Not done                        |
| MASTOID         | Hearing loss, Vertigo                                 | Surgery + RT                    |
| RETROPERITONEUM | Abdominal discomfort                                  | Surgery                         |
| PROSTATE        | Perineal pain, night sweats, rectal fullness, urgency | Surgery                         |
| OVARY           | Pelvic pain   | Surgery                         |
| EYELID          | Swelling  | Surgery                         |
| FOREARM         | Mass, pain, weakness                                  | Surgery                         |
| LIVER           | Altered blood count                                   | Liver transplantation           |
| PLEURA          | Pleural effusion, chylous ascites                     | Chemo (carboplatin + etoposide) |

**HISTOLOGY:** When EHE was identified, electron microscopy showed a typical image of endothelial cells similar to those composing medium-size vessels or a large vein, arranging in nests or cords, while immunohistochemistry revealed Weibel-Palade bodies in the cytoplasm of their cells as a typical finding[9]. A variety of endothelial proteins may be useful to identify EHE. The Flt-1 protein is expressed by the endothelium as well as the T-cells and megakaryocytes: this nuclear protein has proven useful in identifying vascular neoplasm including EHE, showing a better combined sensitivity and specificity than the endothelial markers CD31 and CD34. CD34 is reported to be expressed by more than 90% of vascular tumors, so this marker has poor specificity as a variety of soft tissue tumors also express it. In contrast, CD31 is regarded as a relatively specific vascular tumor marker.

**INVESTIGATIONS:** Blood counts and biochemical profiles are usually normal. The radiology examination with MRI are necessary to obtain morphological data: the degree of the neoformation, the relations with the surrounding tissues, a potential cleavage plane[10].

**TREATMENT:** Because of its rarity, EHE has no standard for treatment and actually few therapeutic options are available. If the proposed association of Bartonella spp. infections were confirmed, it would be plausible that eradicating the bacterial infection or interrupting Bartonella-induced angiogenic and proliferative cell signals could slow the tumor progression and improve patient outcomes[10].

Many cases of hemangioendothelioma are asymptomatic and are treated with a 'wait and see' approach. It is sometimes considered prudent to wait until the hemangioendothelioma declares its intentions, before starting to fight back. However, there are times when treatment may be indicated.

**PROGNOSIS:** Though there is little experience with epithelioid

sarcoma-like hemangioendothelioma, it appears to have in a relatively indolent fashion. Local recurrence and soft tissue metastasis has been reported but not lymph node or distant metastasis. No tumor related deaths have been reported to date, except for lung tumours resulting in respiratory failure[11].

**CONCLUSION:**

If you have isolated disease of hemangioendothelioma, ie a tumor in one place where it can be removed, then surgery to remove the one tumor can be the best chance for a cure and this is almost certainly the way to go.

**REFERENCES:**

1. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor, [Oncology Reviews 2014; 8:259]
2. CRAVAT foundation, overview and updates on EHE.
3. Tsarouha H, Kyriazoglou AI, Pandis N, et al. Chromosomal analysis and molecular cytogenetic investigations of an epithelioid hemangioendothelioma. Cancer Genet Cytogenet 2006;169:1648.
4. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982;50:970-81.
5. Weiss SW, Ishak KG, Enzinger FM, et al. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 1986;3:259-87.
6. Mertens F, Unni K, Fletcher CDM. World Health Organization classification of tumors. Pathology and genetics. Tumors of soft tissue and bone. Lyon: IRAC Press; 2002. p 155.
7. Mukherjee S, Mallick J, Chattopadhyay S, et al. Hemangioendothelioma of soft tissue: Cytological dilemma in two unusual sites. J Cytol 2012;29:89-91.
8. Mascarelli PE, Iredell JR, Breitschwerdt EB, et al. Bartonella species bacteremia in two patients with epithelioid hemangioendothelioma. J Clin Microbiol 2011;49:4006-12.
9. Aquilina K, Lim C, Keohane C, et al. Epithelioid hemangioendothelioma of the spine. J Neurosurg Spine 2005;3:393-9.
10. Gherman CD, Fodor D. Epithelioid hemangioendothelioma of the forearm with radius involvement. Case report. Diagn Pathol 2011;6:120.
11. Mascarelli PE, Iredell JR, Breitschwerdt EB, et al. Bartonella species bacteremia in two patients with epithelioid hemangioendothelioma. J Clin Microbiol 2011;49:4006-12.